The CYP P450 Arachidonate Monooxygenases: Enzymatic Relays for the Control of Kidney Function and Blood Pressure

  • Jorge H. Capdevila
  • Kiyoshi Nakagawa
  • Vijaykumar Holla
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 525)


During P450-dependent metabolism, arachidonic acid (AA) is: a) hydroxylated at its ω or ω-1 carbons to 19- and 20-hydroxyeicosatetraenoic acids (HETEs)(AA ω/ω-1 hydroxylase), or b) epoxidized at any one of its four olefins to 5,6-, 8,9-, 11,12-, or 14,15-epoxyeicosatrienoic acids (EETs)(AA epoxygenase). The demonstration that many of these P450- derived eicosanoids, were formed endogenously by several rat, rabbit, and human tissues, and that they were present in human and rat plasma and/or urine, established the P450 AA monooxygenase as a formal metabolic pathway, and stimulated an extensive functional characterization of its metabolites [1, 2, 3, 4, 5, 6, 7]. During the last 15 years, the list of biological activities attributed to the P450-eicosanoids has increased at a rapid pace, and led to an extensive in vitro characterization of their vasoactive properties, roles in cell and organ ion transport, and of their participation in hormone signaling cascades [1, 2, 3, 4, 5, 6, 7]. In male Sprague-Dawley rats, AA ω/ω-1 hydroxylation and epoxidation account for 70–80, and 20–30% of the total kidney microsomal monooxygenase activity, respectively, and 20-HETE and 11(R), 12(S)-EET (88% optical purity) are recovered as the major ω-hydroxylase and epoxygenase metabolites, respectively [[3]]. The high degree of structural homology displayed by the members of a P450 gene family [8] has complicated the identification of the P450 isoforms responsible for the metabolism of endogenous AA pools [[3],[5],[9]–[11]]. Nevertheless, extensive enzymatic, biochemical, immunological, and functional evidence indicates that CYPs of the 2 and 4 gene families are responsible for AA metabolism, and that, in rat kidney, CYPs 2C and 4A are the predominant and functionally significant AA epoxygenases and ω/ω-1 hydroxylases, respectively [[3],[9]–[19]]. For example, CYPs, 2C23, 2C24, and 2C11 are expressed in the rat kidney in decreasing order of abundance [[17]] but, of these, only CYP 2C23 metabolizes AA with a regio- and enantioselectivity that matches that of the microsomal enzymes [[16],[17]]. Furthermore, as shown in Figure 1,antibodies raised against CYP 2C23 inhibited better than 95% of the microsomal epoxygenase activity present in rat kidney microsomes, and had no effect on microsomal AA ω/ω-1 hydroxylation. The recognition of CYPs 2C and 4A as endogenous AA epoxygenases and ω/ hydroxylases, as well the early proposal of a role for these isoforms in the pathophysiology of experimental hypertension [1,[4]–[7]], open the way to the introduction of molecular approaches for the study of the functional roles of the AA monooxygenases, and the characterization of P450-isoform/gene-dependent phenotypes of renal dysfunction.


Arachidonic Acid Salt Sensitive Hypertension Epoxyeicosatrienoic Acid Plasma Androgen Level Endogenous Arachidonic Acid 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    McGiff JC and Quilley J. 20-HETE and the kidney: resolution of old problems and new beginnings. Am J Physiol 1999; 277:R607–R623, and cited referencesPubMedGoogle Scholar
  2. 2.
    Campbell WB and Harder DR. Endothelium-derived hyperpolarizing factors and vascular cytochrome P450 metabolites of arachidonic acid in the regulation of tone. Circ Res 1999; 84:484–488, and cited references.PubMedCrossRefGoogle Scholar
  3. 3.
    Capdevila JH, Falck JR, and Harris RC. Cytochrome P450 and arachidonic acid bioactivation: molecular and functional properties of the arachidonate monooxygenase. J Lipid Res 2000; 41:163–181, and cited references.PubMedGoogle Scholar
  4. 4.
    Imig JD. Eicosanoid regulation of renal vasculature. Am J Physiol 2000; 279:F965–F981, and cited references.Google Scholar
  5. 5.
    Capdevila JH and Falck JR. The CYP P450 arachidonic acid monooxygenases: From cell signaling to blood pressure regulation. Biochem Biophys Res Comm 2001; 285:571–576, and cited references.PubMedCrossRefGoogle Scholar
  6. 6.
    McGiff JC and Quilley J. 20-Hydroxyeicosatetraenoic acid and epoxyeicosatrienoic acids and blood pressure. Curr Opin Nephrol Hypertens 2001; 10:231–237, and cited references.PubMedCrossRefGoogle Scholar
  7. 7.
    Roman, RJ. P450 Metabolites of Arachidonic Acid in the Control of Cardiovascular Function. Physiol Rev 2002; 82:131–185, and cited references.PubMedGoogle Scholar
  8. 8.
    An updated list of P450 informs, sequences, gene structures, etc can be found at: Scholar
  9. 9.
    Capdevila JH, Karara A, Waxman DJ, Martin MV, Falck JR, and Guengerich FP. Cytochrome P-450 enzyme-specific control of the regio-and enantiofacial selectivity of the microsomal AA epoxygenase. J Biol Chem 1990; 265:10865–10871PubMedGoogle Scholar
  10. 10.
    Zeldin DC. Epoxygenase Pathways of Arachidonic Acid Metabolism. J Biol Chem 2001; 276:36059–36062, and cited references.PubMedCrossRefGoogle Scholar
  11. 11.
    Karara A, Dishman E, Blair IA, Falck JR, and Capdevila JH. Endogenous epoxyeicosatrienoic acids. Cytochrome P450 controlled stereoselectivity of the hepatic arachidonic acid epoxygenase. J Biol Chem 1989; 264:19822–19827.PubMedGoogle Scholar
  12. 12.
    Stromsteadt M, Hayashi S, Zaphiropoulos PG, and Gustafsson JA. Cloning and characterization of a novel member of the cytochrome P450 subfamily IVA in rat prostate. DNA Cell Biol 1990; 8:569–577.CrossRefGoogle Scholar
  13. 13.
    Wang MH, Stec DE, Balazy M, Mastyugin V, Yang CS, Roman RJ, and Schwartzman ML. Cloning, sequencing, and cDNA-directed expression of rat renal CYP4A2: AA ω-hydroxylation and 11,12-epoxidation by CYP4A2 protein. Arch Biochem Biophys 1997; 336: 240–250.CrossRefGoogle Scholar
  14. 14.
    Helvig C, Dishman E, and Capdevila JH. Molecular, enzymatic, and regulatory characterization of rat kidney cytochromes P450 4A2 and 4A3. Biochemistry 1998; 37:12546–12558.PubMedCrossRefGoogle Scholar
  15. 15.
    Hoch U, Zhang Z, Kroetz DL, and Ortiz de Montellano, PR. Structural determination of the substrate specificities and regioselectivities of the rat and human fatty acid omega hydroxylases. Arch Biochem Biophys 2000; 373:63–71.PubMedCrossRefGoogle Scholar
  16. 16.
    Karara A, Makita K, Jacobson HR, Falck JR, Guengerich FP, DuBois RN, and Capdevila JH. Molecular cloning, expression, and enzymatic characterization of the rat kidney cytochrome P-450 AA epoxygenase. J Biol Chem 1993; 268:13565–13570.PubMedGoogle Scholar
  17. 17.
    Holla VR, Makita K, Zaphiropoulos PG, and Capdevila JH. The kidney cytochrome P450 2C23 AA epoxygenase is upregulated during dietary salt loading. J Clin Invest 1999; 104:751–760PubMedCrossRefGoogle Scholar
  18. 18.
    Tsao CC, Coulter SJ, Chien A, Luo G, Clayton NP, Maronpot R, Goldstein JA, and Zeldin DC. Identification and Localization of Five CYP2Cs in Murine Extrahepatic Tissues and Their Metabolism of Arachidonic Acid to Regio-and Stereoselective Products. J. Pharmacol Expt Ther 2001; 299:39–47.Google Scholar
  19. 19.
    Makita K, Takahashi K, Karara A, Jacobson HR, Falck JR, and Capdevila JH. Experimental and/or genetically controlled alterations of the renal microsomal cytochrome P450 epoxygenase induce hypertension in rats fed a high salt diet. J Clin Invest 1994; 94:2414–2420.PubMedCrossRefGoogle Scholar
  20. 20.
    Campbell WB, Gebremedhin D, Pratt PF, and Harder DR. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Cir. Res. 1996; 78:415–423.CrossRefGoogle Scholar
  21. 21.
    Fisslthaler B, Popp R. Kiss L, Potente M, Harder DR, Fleming I, and Busse R. Cytochrome P450 2C is an EDHF synthase in coronary arteries. Nature 1999; 410:493–497.Google Scholar
  22. 22.
    Imig JD, Falck JR, Wei S, and Capdevila JH. Epoxygenase metabolites Contribute to Nitric Oxide-Independent Afferent Arteriolar Vasodilation in Response to Bradykinin. J Vasc Res 2001; 38:247–255.PubMedCrossRefGoogle Scholar
  23. 23.
    Okeyan AO, McGiff JC, and Quilley J. Cytochrome P450-depedent vasodilator responses to arachidonic acid in the isolated perfused kidney of the rat. Circ Res 1991; 68:958–965.CrossRefGoogle Scholar
  24. 24.
    Okeyan AO, and McGiff JC. Functional response of the rat kidney to inhibition of nitric oxide synthesis: Role of cytochrome P450-derived arachidonate metabolites. Br J Pharmacol 1998; 125:1065–1073.CrossRefGoogle Scholar
  25. 25.
    Holla VR, Adas F, Imig JD, Zhao X, Price E, Olsen N, Kovacs WJ, Magnuson MA, Keeney DS, Breyer MD, Falck JR, Waterman MR, and Capdevila JH. Alterations in the regulation of androgen-sensitive Cyp 4a monooxygenases cause hypertension. Proc Nat Acad Scie (USA) 2001; 98:5211–5216.CrossRefGoogle Scholar
  26. 26.
    Nakawaga k, Matji JS, Schwartzman ML, Waterman MR, and Capdevila JH. The Androgen-mediated Induction of Kidney Arachidonate hydroxylases is Associated with the Development of Hypertension. J Am Physiol 2002, (Submitted).Google Scholar
  27. 27.
    Sacerdoti D. Abrahm, NG, McGiff JC, and Schwartzman ML. Renal cytochrome P-450-depedent metabolism of arachidonic acid in spontaneously hypertensive rats. Biochem Pharmacol 1988; 37:521–527.PubMedCrossRefGoogle Scholar
  28. 28.
    Iwai N, and Inagami T. Isolation of preferentially expressed genes in the kidneys of hypertensive rats. Hypertension 1991; 17:161–169.PubMedCrossRefGoogle Scholar
  29. 29.
    Su, Kaushal KM, and Kroetz DL. Inhibition of renal arachidonic acid omegahydroxylase activity with ABT reduces blood pressure in the SHR. Am. J. Physiol. 1998;275:R426–R438.PubMedGoogle Scholar
  30. 30.
    Wang MH, Zhang F, Marji J, Zand BA, Nasjletti A, and Laniado-Schwartzman M. CYP4A1 antisense oligonucleotide reduces mesenteric vascular reactivity and blood pressure in SHR. Am J Physiol 2001; 280:255–261.Google Scholar
  31. 31.
    Henderson CJ, Scott AR, Yang CS, and Wolf CR. Testosterone-mediated regulation of mouse renal cytochrome P-450 isoenzymes. Biochem J 1990; 266:675–681.PubMedGoogle Scholar
  32. 32.
    Henderson CJ and Wolf CR. Evidence that the androgen receptor mediates sexual differentiation of mouse renal cytochrome P450 expression. Biochem J 1991; 278:499–503.PubMedGoogle Scholar
  33. 33.
    Sundseth SS and Waxman DJ. Sex-dependent expression and Clofibrate inducibility of cytochrome P450 AA fatty acid D-hydroxylases. J Biol Chem 1992; 267(6):3915–3921.PubMedGoogle Scholar
  34. 34.
    Kroetz DL, Yook P, Costet P, Bianchi P, and Pineau T. Peroxisome proliferator-activated receptor alpha controls hepatic CYP4A induction adaptive response to starvation and diabetes. J Biol Chem 1998; 273:31581–31589.PubMedCrossRefGoogle Scholar
  35. 35.
    Corton JC, Fan L.-Q, Brown S, Anderson SP, Bocos C, Cattley RC, Mode A, and Gustafsson J-A. Down-Regulation of Cytochrome P450 2C Family Members and Positive Acute-Phase Response Gene Expression by Peroxisomal Proliferator Chemicals. Mol Pharm 1998; 54:463–473.Google Scholar
  36. 36.
    Shatara RK, Quest DW, and Wilson TW. Fenofibrate lowers blood pressure in two genetic models of hypertension. Can J Physiol Pharmacol 2000; 78:367–371.PubMedCrossRefGoogle Scholar
  37. 37.
    Roman RJ, Ma YH, Fröhlich B, and Markham B. Clofibrate prevents the development of hypertension in Dahl salt-sensitive rats. Hypertension 1993; 21:985–988.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2003

Authors and Affiliations

  • Jorge H. Capdevila
    • 1
  • Kiyoshi Nakagawa
    • 1
  • Vijaykumar Holla
    • 1
  1. 1.Department of MedicineVanderbilt University Medical SchoolNashvilleUSA

Personalised recommendations